Maximizing the potential of aggressive mouse tumor models in preclinical drug testing

Abstract Atypical teratoid rhabdoid tumor (ATRT) is an aggressive embryonal brain tumor among infants and young children. Two challenges exist for preclinical testing in ATRT. First, genetically quiet, ATRT is a difficult tumor to target molecularly. Tumor cells need to divide to propagate tumor gro...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M. Tarek Elghetany, Jia-Min Ho, Lois Hew Shi-Qi, Sekar Karthik, Jack M. F. Su, Qi Lin, YuChen Du, Jianhe Shen, Wing-Yuk Chow, Ching C. Lau, Adekunle Adesina, Angela Major, Anat Erdreich-Epstein, Kam-Man Hui, Xiao-Nan Li, Wan-Yee Teo
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/de5f4ee8efbe4626bc463e33bc5fd9a4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:de5f4ee8efbe4626bc463e33bc5fd9a4
record_format	dspace
spelling	oai:doaj.org-article:de5f4ee8efbe4626bc463e33bc5fd9a42021-12-02T17:50:41ZMaximizing the potential of aggressive mouse tumor models in preclinical drug testing10.1038/s41598-021-91167-62045-2322https://doaj.org/article/de5f4ee8efbe4626bc463e33bc5fd9a42021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91167-6https://doaj.org/toc/2045-2322Abstract Atypical teratoid rhabdoid tumor (ATRT) is an aggressive embryonal brain tumor among infants and young children. Two challenges exist for preclinical testing in ATRT. First, genetically quiet, ATRT is a difficult tumor to target molecularly. Tumor cells need to divide to propagate tumor growth—intercepting the common crossroads in cell cycle progression is a feasible strategy. KIF11 is needed for bipolar spindle formation in metaphase. We identified KIF11 as a universal target of all ATRT-molecular-subtypes. Ispinesib, a KIF11-inhibitor, effectively inhibited tumor proliferation in all seven cell lines. A second challenge—a major challenge in preclinical drug testing in-vivo among aggressive tumor models, is the narrow therapeutic window to administer drugs within the limited murine lifespan. Our most aggressive ATRT tumor model was lethal in all mice within ~ 1 month of tumor implantation. Such short-surviving mouse models are difficult to employ for preclinical drug testing due to the narrow time window to administer drugs. To overcome this time restriction, we developed a clinical staging system which allowed physically-fit mice to continue treatment, in contrast to the conventional method of fixed drug-dose-duration regimen in preclinical testing which will not be feasible in such short-surviving mouse models. We validated this approach in a second embryonal brain tumor, medulloblastoma. This is a clinically relevant, cost-efficient approach in preclinical testing for cancer and non-cancer disease phenotypes. Widely used preclinical mouse models are not the most accurate and lack the aggressive tumor spectrum found within a single tumor type. Mice bearing the most aggressive tumor spectrum progress rapidly in the limited murine life-span, resulting in a narrow therapeutic window to administer drugs, and are thus difficult to employ in preclinical testing. Our approach overcomes this challenge. We discovered ispinesib is efficacious against two embryonal brain tumor types.M. Tarek ElghetanyJia-Min HoLois Hew Shi-QiSekar KarthikJack M. F. SuQi LinYuChen DuJianhe ShenWing-Yuk ChowChing C. LauAdekunle AdesinaAngela MajorAnat Erdreich-EpsteinKam-Man HuiXiao-Nan LiWan-Yee TeoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q M. Tarek Elghetany Jia-Min Ho Lois Hew Shi-Qi Sekar Karthik Jack M. F. Su Qi Lin YuChen Du Jianhe Shen Wing-Yuk Chow Ching C. Lau Adekunle Adesina Angela Major Anat Erdreich-Epstein Kam-Man Hui Xiao-Nan Li Wan-Yee Teo Maximizing the potential of aggressive mouse tumor models in preclinical drug testing
description	Abstract Atypical teratoid rhabdoid tumor (ATRT) is an aggressive embryonal brain tumor among infants and young children. Two challenges exist for preclinical testing in ATRT. First, genetically quiet, ATRT is a difficult tumor to target molecularly. Tumor cells need to divide to propagate tumor growth—intercepting the common crossroads in cell cycle progression is a feasible strategy. KIF11 is needed for bipolar spindle formation in metaphase. We identified KIF11 as a universal target of all ATRT-molecular-subtypes. Ispinesib, a KIF11-inhibitor, effectively inhibited tumor proliferation in all seven cell lines. A second challenge—a major challenge in preclinical drug testing in-vivo among aggressive tumor models, is the narrow therapeutic window to administer drugs within the limited murine lifespan. Our most aggressive ATRT tumor model was lethal in all mice within ~ 1 month of tumor implantation. Such short-surviving mouse models are difficult to employ for preclinical drug testing due to the narrow time window to administer drugs. To overcome this time restriction, we developed a clinical staging system which allowed physically-fit mice to continue treatment, in contrast to the conventional method of fixed drug-dose-duration regimen in preclinical testing which will not be feasible in such short-surviving mouse models. We validated this approach in a second embryonal brain tumor, medulloblastoma. This is a clinically relevant, cost-efficient approach in preclinical testing for cancer and non-cancer disease phenotypes. Widely used preclinical mouse models are not the most accurate and lack the aggressive tumor spectrum found within a single tumor type. Mice bearing the most aggressive tumor spectrum progress rapidly in the limited murine life-span, resulting in a narrow therapeutic window to administer drugs, and are thus difficult to employ in preclinical testing. Our approach overcomes this challenge. We discovered ispinesib is efficacious against two embryonal brain tumor types.
format	article
author	M. Tarek Elghetany Jia-Min Ho Lois Hew Shi-Qi Sekar Karthik Jack M. F. Su Qi Lin YuChen Du Jianhe Shen Wing-Yuk Chow Ching C. Lau Adekunle Adesina Angela Major Anat Erdreich-Epstein Kam-Man Hui Xiao-Nan Li Wan-Yee Teo
author_facet	M. Tarek Elghetany Jia-Min Ho Lois Hew Shi-Qi Sekar Karthik Jack M. F. Su Qi Lin YuChen Du Jianhe Shen Wing-Yuk Chow Ching C. Lau Adekunle Adesina Angela Major Anat Erdreich-Epstein Kam-Man Hui Xiao-Nan Li Wan-Yee Teo
author_sort	M. Tarek Elghetany
title	Maximizing the potential of aggressive mouse tumor models in preclinical drug testing
title_short	Maximizing the potential of aggressive mouse tumor models in preclinical drug testing
title_full	Maximizing the potential of aggressive mouse tumor models in preclinical drug testing
title_fullStr	Maximizing the potential of aggressive mouse tumor models in preclinical drug testing
title_full_unstemmed	Maximizing the potential of aggressive mouse tumor models in preclinical drug testing
title_sort	maximizing the potential of aggressive mouse tumor models in preclinical drug testing
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/de5f4ee8efbe4626bc463e33bc5fd9a4
work_keys_str_mv	AT mtarekelghetany maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT jiaminho maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT loishewshiqi maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT sekarkarthik maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT jackmfsu maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT qilin maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT yuchendu maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT jianheshen maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT wingyukchow maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT chingclau maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT adekunleadesina maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT angelamajor maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT anaterdreichepstein maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT kammanhui maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT xiaonanli maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT wanyeeteo maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting
_version_	1718379319293640704

Maximizing the potential of aggressive mouse tumor models in preclinical drug testing

Ejemplares similares